Details for Patent: 11,185,497

✉ Email this page to a colleague

Which drugs does patent 11,185,497 protect, and when does it expire?

Patent 11,185,497 protects TRUDHESA and is included in one NDA.

This patent has thirteen patent family members in ten countries.

Summary for Patent: 11,185,497

Patent landscape, scope, and claims:

Title:	Intranasal delivery of dihydroergotamine by precision olfactory device
Abstract:	Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (C.sub.max) of at least 750 pg/ml, (b) with a mean time to C.sub.max (T.sub.max) of DHE of less than 45 minutes, and (c) a mean plasma AUC.sub.0-inf of DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.
Inventor(s):	Hoekman; John D. (Seattle, WA), Satterly; Kelsey H. (Seattle, WA), Shrewsbury; Stephen B. (Fallbrook, CA), Youmans; Scott (Bothell, WA), Fuller; Christopher (Seattle, WA)
Assignee:	Impel Neuropharma, Inc. (Seattle, WA)
Application Number:	17/062,364
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Delivery; Device;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 11,185,497

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes	11,185,497	⤷ Subscribe				NASAL ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE BY METERED SPRAY FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,185,497

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019205318	⤷ Subscribe
Australia	2022202900	⤷ Subscribe
Brazil	112020013744	⤷ Subscribe
Canada	3088942	⤷ Subscribe
China	111936140	⤷ Subscribe
European Patent Office	3735244	⤷ Subscribe
European Patent Office	4147699	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.